SREBF1 and melanoma: The pharmacological inhibition of SREBP-1 with fatostatin enhances the responsiveness of B-RafV600E-mutant, therapy-resistant melanoma to B-RafV600E inhibitors, both in vitro and in preclinical patient-derived xenograft models in vivo [85].